- Preclinical data showing how ERA(TM), eTurna(TM) technologies turbocharge 
T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting 
today
- ERA(TM) boosts CAR T-cell efficacy by overcoming T-cell exhaustion that 
inhibits cancer cures
- eTurna(TM) delivery platform delivers more healthy, functional T-cells than 
electroporation, without the safety risks of viral vectors
- Use of both technologies has the potential to lower cost of T-cell therapies, 
expand patient access
 
Turn Biotechnologies, a cell rejuvenation company developing novel mRNA 
medicines to cure untreatable, age-related conditions, today presents interim 
pre-clinical data that demonstrates treating T cells with its proprietary 
technologies can significantly increase their ability to kill cancer.

Photo - https://mma.prnewswire.com/media/1927460/GettyImages_1227506537.jpg

The data show that using Turn Bio's Epigenetic Reprogramming of Aging (ERA(TM)) 
technology and its eTurna(TM) delivery platform in the manufacture of T cells 
can produce and deliver more effective therapies more efficiently. The findings 
promise to help reduce the cost of T-cell therapies and make them more 
accessible to cancer patients.

"Our data show that using ERA technology and our eTurna delivery platform can 
overcome the fundamental problem of T-cell exhaustion and aging that limit the 
efficacy and long-term effectiveness of CAR-T therapies," said Vittorio 
Sebastiano, company co-founder and head of research. "ERA provides the 
opportunity for enhanced dose management and optimization with the ability to 
personalize dosing to maximize efficiency without compromising patient safety.

"We found eTurna preserves T-cell health and functionality better than 
electroporation, facilitating greater cell viability and production during CAR 
T manufacturing," he said. "It also provides superior safety compared to viral 
gene delivery, thus mitigating many manufacturing, biological and regulatory 
challenges."

Sebastiano's presentation, "First Look Data: Epigenetic Reprogramming of Aging 
(ERA) – A New Paradigm in Cell Rejuvenation," takes place at New Frontiers of 
RNA Nanotherapeutics, at 10 a.m. CST at Houston Methodist Research Institute.

Turn Bio's technologies were applied concurrently with the CAR T-cell 
manufacturing process, which demonstrates that T-cell immunotherapy products 
can be enhanced without additional time or facilities beyond those already 
needed for manufacturing.

The company's process can transfect immune cells with rates as high as 
industry-standard electroporation, but with no cytotoxicity. The eTurna 
Platform(TM) was used to precisely control timing, duration and activation of 
the ERA factor cocktail while preserving cellular identity.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the 
cellular level and developing transformative drug delivery systems. The 
company's proprietary mRNA platform technology, ERA(TM), restores optimal gene 
expression by combatting the effects of aging in the epigenome. This restores 
cells' ability to prevent or treat disease and heal or regenerate tissue. Its 
eTurna(TM) Delivery Platform uses unique formulations to precisely deliver 
cargo to specific organs, tissues and cell types.

The company is completing pre-clinical research on tailored therapies targeting 
indications in dermatology and immunology, and developing therapies for 
ophthalmology, osteo-arthritis and the muscular system. For more information, 
see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup
jim@rightstorygroup.com or (312) 543-9026

SOURCE Turn Biotechnologies, Inc.